Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer

Authors:
  • YYYasuhide Yamada
    Yasuhide Yamada
  • NONatuko T. Okita
    Natuko T. Okita
  • THTakuya Honda
    Takuya Honda
  • YHYoshinori Hirashima
    Yoshinori Hirashima
  • JMJunichi Matsubara
    Junichi Matsubara
  • ATAtsuo Takashima
    Atsuo Takashima
  • KKKen Kato
    Ken Kato
  • THTetsuya Hamaguchi
    Tetsuya Hamaguchi
  • KSKuniaki Shirao
    Kuniaki Shirao
  • YSYasuhiro Shimada
    Yasuhiro Shimada
  • TSTadakazu Shimoda
    Tadakazu Shimoda

Abstract
Objectives: The present study evaluated the prognostic implications of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER)-2 in patients with colorectal cancer (CRC). Methods: Our subjects were 91 patients who underwent surgery and subsequently received fluoropyrimidines. Expressions of IGF-1R, EGFR and HER-2 in primary lesions were analyzed immunohistochemically to determine the prognostic significance of these biomarkers. Results: Overexpression was found for IGF-1R in 48 tumors (53%), EGFR in 57 (63%) and HER-2 in 2 (2%). Overexpression of IGF-1R was significantly correlated with shorter survival from the start of first-line chemotherapy (p = 0.033). Overexpression of EGFR was a significant predictor of clinical response to fluoropyrimidines (p = 0.032). Multivariate analysis of potential prognostic factors showed that IGF-1R expression and worsened performance status were independent predictors of poor outcomes. Conclusions: Our results suggest that anti-IGF-1R strategies may offer a useful approach in molecular therapy for CRC, which has the potential to improve outcomes.